214lbs => 69] (5months) glp1 med, diet, lots of exercise. : r/progresspics My first year off GLPs" loading="eager" fetchpriority="high" decoding="async"/>
glp 1 reddit bodybuilding M/38/6'1" [283lbs (-)> 214lbs => 69] (5months) glp1 med, diet, lots of exercise. : r/progresspics My first year off GLPs
Description
However, before those trials can move forward, Judge Marston has ordered both sides to resolve several issues that could have broad implications for the litigation, including preemption and general causation
![glp 1 reddit bodybuilding M/38/6'1" [283lbs (-)> 214lbs => 69] (5months) glp1 med, diet, lots of exercise. : r/progresspics My first year off GLPs](https://preview.redd.it/my-first-year-off-glps-success-story-ama-v0-kd53v7j06y2f1.jpg?width=2048&format=pjpg&auto=webp&s=520aad83b852524c61418601bf9eeb569c02d5f5)
The therapeutic efficacy of GLP-1 is well established (3-5), and epigenetic modulation to amplify GLP-1 receptor (GLP-1R) action has been advocated as an option for the long-term glycemic control and reduction of obesity (6)
![glp 1 reddit bodybuilding M/38/6'1" [283lbs (-)> 214lbs => 69] (5months) glp1 med, diet, lots of exercise. : r/progresspics My first year off GLPs](https://preview.redd.it/125-pounds-down-in-1-year-cico-glp-1-v0-k1kaw94y6pug1.png?width=640&crop=smart&auto=webp&s=a968bbd7f8c33eaf70ac0fb1e6aed33bd805f3b1)
Healthcare system metrics and incentives rarely reward obesity management activities
![glp 1 reddit bodybuilding M/38/6'1" [283lbs (-)> 214lbs => 69] (5months) glp1 med, diet, lots of exercise. : r/progresspics My first year off GLPs](https://i.redd.it/glp-1-weight-loss-motivation-v0-3cxhx6p68nld1.jpg?width=2581&format=pjpg&auto=webp&s=bf22a812d3d365dcef3e339fca0e7d3a0759f87a)
Other side effects shared in these reviews include heart palpitations, sweating, nausea, shortness of breath, and fatigue
![glp 1 reddit bodybuilding M/38/6'1" [283lbs (-)> 214lbs => 69] (5months) glp1 med, diet, lots of exercise. : r/progresspics My first year off GLPs](https://i.ytimg.com/vi/HGDH3L9ywME/sddefault.jpg)
However, it remains unknown whether hepatic GLP-1 resistance contributes to the poor treatment efficiency of GLP-1 in these patients
Currently, several obesity companies, such as YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis,, and others, across the globe are developing obesity therapies